Inavolisib (NCT07748208)

Name: Inavolisib trial for Breast Cancer (NCT07748208)
Uploaded: 2026-10-31T21:19:10.905Z
Duration: 1 min 35 s
Description: Inavolisib trial for Breast Cancer (NCT07748208). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07748208.

A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes: a one-minute explainerNCT077482081 min

Inavolisib trial for Breast Cancer (NCT07748208). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with PIK3CA-mutated, hormone-receptor-positive, HER2-negative advanced breast cancer and controlled type 2 diabetes. The three-drug group excludes previous systemic treatment for advanced disease.

The idea: oral inavolisib blocks PI3K growth signals, while injected fulvestrant blocks estrogen receptors. Some patients also take palbociclib, which blocks CDK4/6 to slow cell division. Researchers focus on severe high blood sugar, related hospital admissions and other side effects.

This phase 2 study plans 40 patients. Hoffmann-La Roche sponsors it, with nine recruiting US sites. The study team must check diabetes medicines and blood-test eligibility.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.